Lung cancer showdown: which drug combo works best?
NCT ID NCT07394062
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 400 people with advanced non-small cell lung cancer whose tumors have low PD-L1 levels (below 50%). Researchers will compare two standard treatment combos: chemotherapy plus pembrolizumab versus nivolumab plus ipilimumab with chemotherapy. The goal is to see which approach leads to longer survival and better quality of life in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab, nivolumab, ipilimumab, and platinum-based chemotherapy
- What this could lead to
- If successful, this study could help doctors choose the best treatment for advanced lung cancer patients with low PD-L1 levels, improving survival and quality of life.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by patient differences. It won't prove one treatment is better, only provide real-world insights.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NONSMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ankara Etlik City Hospital
RECRUITINGAnkara, Turkey (Türkiye)
-
Gazi University Faculty of Medicine, Department of Medical Oncology
RECRUITINGAnkara, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.